知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

282 条记录 (耗时 0.028 秒)

    Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
    72.
    发明授权
    Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same 有权
    己基-5-氨基乙酰丙酸盐酸盐的形式及其使用方法

    公开(公告)号：US08927761B2

    公开(公告)日：2015-01-06

    申请号：US13930497

    申请日：2013-06-28

    申请人： Stephan D. Parent ,  Jon Erik Brænden

    发明人： Stephan D. Parent ,  Jon Erik Brænden

    IPC分类号： C07C229/22 ,  A61K49/00 ,  A61K41/00

    CPC分类号： C07C229/22 ,  A61K41/0061 ,  A61K49/0052 ,  C07B2200/13

    摘要： This invention relates to a novel crystalline polymorph of hexyl-5-aminolevulinate hydrochloride, referred to hereinafter as Form C, which is useful as precursor of a photo sensitizer in the photodynamic diagnosis and treatment of metabolically active cells related to diseases such as cancer of the uterus, cervix, vagina, rectum, colon, lower gastrointestinal tract; infection associated with cancer caused by human papilloma virus; non-cancerous lower gastrointestinal tract a human; inflammatory bowel disease; ulcerative colitis; Crohn's disease; inflammatory bowel syndrome; dysplasia of the female reproductive system; anus; penis; rosacea; and acne and which is suitable for use as the active ingredient of a commercial pharmaceutical product. The invention relates further to methods of preparing Form C and using it in the described pharmaceutical compositions.

    摘要翻译： 本发明涉及一种新型的5-己基-5-氨基乙酰丙酸盐酸盐的结晶多晶型物，以下称为C型，其可用作光致敏剂的前体，用于光动力学诊断和治疗与诸如癌症的疾病相关的代谢活性细胞 子宫，子宫颈，阴道，直肠，结肠，下胃肠道; 与人乳头状瘤病毒引起的癌症相关的感染; 非癌性下胃肠道一人; 炎症性肠病; 溃疡性结肠炎 克罗恩病; 炎性肠综合征; 女性生殖系统发育异常; 肛门; 阴茎 红斑痤疮 和粉刺，并且其适合用作商业药物产品的活性成分。 本发明进一步涉及制备形式C并将其用于所述药物组合物中的方法。

    THERAPEUTIC AGENT FOR ALLERGIC RHINITIS
    74.
    发明申请
    THERAPEUTIC AGENT FOR ALLERGIC RHINITIS 有权
    用于过敏性RHINITIS的治疗剂

    公开(公告)号：US20140188034A1

    公开(公告)日：2014-07-03

    申请号：US14125744

    申请日：2012-06-15

    申请人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    发明人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    IPC分类号： A61K41/00 ,  A61N5/06

    CPC分类号： A61N5/062 ,  A61K9/0043 ,  A61K9/06 ,  A61K41/0061 ,  F04C2270/0421

    摘要： Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.

    摘要翻译： 本发明提供能够以安全，简单，无创的方式治疗过敏性鼻炎的治疗剂，其基本上无副作用和对患者的身体伤害。 本发明提供了包含5-氨基乙酰丙酸（ALA）或其衍生物的5-氨基乙酰丙酸类光动力治疗（ALA-PDT）或5-氨基乙酰丙酸或其衍生物的活性成分的过敏性鼻炎的治疗剂 成分，并用于其中照射波长为400nm至700nm的光的ALA-PDT中; 并且特别提供了局部施用的溶液形式的过敏性鼻炎的治疗剂，溶于水的软膏溶解形式，果冻溶解形式等。 治疗剂不需要进行基于5-氨基乙酰丙酸的光动力学诊断（ALA-PDD），用于检测在具有610nm至650nm的波长的照射下发射具有波长为610nm至650nm的光的原卟啉IX（PpIX）积累的位点， 在ALA-PDT之前的波长为380nm至420nm。

    PHOTODYNAMIC THERAPY OR DIAGNOSTIC AGENT, USING INFRARED-SPECTRUM LIGHT
    75.
    发明申请
    PHOTODYNAMIC THERAPY OR DIAGNOSTIC AGENT, USING INFRARED-SPECTRUM LIGHT 有权
    光化学治疗或诊断剂，使用红外光谱

    公开(公告)号：US20140056817A1

    公开(公告)日：2014-02-27

    申请号：US14113877

    申请日：2012-04-27

    申请人： Hideya Yuasa ,  Shun-ichiro Ogura ,  Kiwamu Takahashi ,  Katushi Inoue ,  Tohru Tanaka

    发明人： Hideya Yuasa ,  Shun-ichiro Ogura ,  Kiwamu Takahashi ,  Katushi Inoue ,  Tohru Tanaka

    IPC分类号： A61K31/409 ,  A61K49/00 ,  A61K31/197

    CPC分类号： A61K31/409 ,  A61K31/197 ,  A61K41/0061 ,  A61K41/0071 ,  A61K49/0019 ,  A61K49/0021 ,  A61K49/0052 ,  A61K49/0093

    摘要： It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 μm to 2.5 μm; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group.

    摘要翻译： 旨在提供可用于能够利用红外光谱（例如近红外光（NIR），红外光或远）的光动力学治疗（PDT）或光动力学诊断（PDD）的治疗和/或诊断剂 - 红外光，其深度穿透力。 本发明提供了一种用于癌症或感染性疾病的光动力学治疗或诊断剂或光动力学治疗或诊断试剂盒，其包括：通过红外光谱如近红外光发射上转换发光的颗粒（例如镧系元素颗粒），其具有 波长0.7μm至2.5μm; 和光敏剂（例如卟啉）或5-氨基乙酰丙酸基团。

    SOLID COMPOSITIONS COMPRISING 5-AMINOLEVULINIC ACID
    79.
    发明申请
    SOLID COMPOSITIONS COMPRISING 5-AMINOLEVULINIC ACID 审中-公开
    包含5-氨基酸的固体组合物

    公开(公告)号：US20120134921A1

    公开(公告)日：2012-05-31

    申请号：US13377692

    申请日：2010-06-11

    申请人： Oddveig Sellaeg Helland ,  Gry Stensrud ,  Bjorn Klem ,  Jon Erik Braenden ,  Aslak Godal ,  Jo Klavenes

    发明人： Oddveig Sellaeg Helland ,  Gry Stensrud ,  Bjorn Klem ,  Jon Erik Braenden ,  Aslak Godal ,  Jo Klavenes

    IPC分类号： A61K51/04 ,  A61K49/00

    CPC分类号： A61K31/197 ,  A61K9/0009 ,  A61K9/4858 ,  A61K41/0061 ,  A61K49/0036

    摘要： This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions of the lower gastrointestinal tract, wherein the solid pharmaceutical compositions and pharmaceutical products are used.

    摘要翻译： 本发明涉及用于癌症的光动力学诊断方法，胃肠系统下部癌前和非癌症病症的固体组合物和固体药物产品。 固体药物组合物和药物产品包含5-氨基乙酰丙酸（5-ALA）或5-ALA的前体或衍生物的活性成分或其药学上可接受的盐。 本发明还涉及癌症的光动力学诊断方法，下胃肠道的癌前和非癌症状况，其中使用固体药物组合物和药物产品。

    Photosensitizer formulations and their use
    80.
    发明授权
    Photosensitizer formulations and their use 有权
    光敏剂配方及其用途

    公开(公告)号：US07825153B2

    公开(公告)日：2010-11-02

    申请号：US11153703

    申请日：2005-06-15

    申请人： Nikolay Nifantiev ,  Volker Albrecht

    发明人： Nikolay Nifantiev ,  Volker Albrecht

    IPC分类号： A61K31/409

    CPC分类号： A61K31/195 ,  A61K31/366 ,  A61K31/409 ,  A61K41/0057 ,  A61K41/0061 ,  A61K41/0071

    摘要： A low concentration formulation for hydrophobic photosensitizers (PS) and method for photodynamic therapy (“PDT”) using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. The inventive formulation (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue and (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. The inventive formulation reduces the time interval between PS application/administration and irradiation (the drug-light interval or “DLI”) and can provide for a “same day” PDT treatment option. 0.08 mg/ml to 1.3 mg/ml meta Tetra-Hydroxy-Phenyl Chlorin (m-THPC) as the photosensitizer in a mixture of pure propylene glycol and ethanol (3:2 volume ratio) accumulates in diseased tissue and differentiates between diseased tissue and normal tissue sufficiently quickly for ‘one day’ or overnight administration and activation treatment procedures to be possible.

    摘要翻译： 使用所公开的低浓度制剂的疏水性光敏剂（PS）和光动力学治疗（“PDT”）的低浓度制剂提供更准确，更有效和更方便的给药。 本发明的制剂（1）减少治疗有效水平的光敏剂积累在患病组织中的时间，和（2）减少在患病组织与健康组织中获得足够比例的光敏剂的时间。 本发明的配方减少PS施用/施用和照射之间的时间间隔（药物光间隔或“DLI”），并且可以提供“同一天”PDT治疗选择。 在纯丙二醇和乙醇（3:2体积比）的混合物中作为光敏剂的间 - 四羟基苯基二氢卟酚（m-THPC）的0.08mg / ml至1.3mg / ml在患病组织中积累并分化为患病组织和 正常组织足够快地“一天”或过夜施用和活化处理程序是可能的。